Regular Insulin vs Rapid Insulin Delivered by V-Go

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT03495908

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
East Coast Institute for Research (from the registry)
Registry
  • NCT NCT03495908
Other papers using this trial's data
  • Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes BMJ open diabetes research & care, 2020-11 DOI, PubMed 33214190, PMC7678232 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03495908. Randomized; no masking; primary purpose treatment. Start 2018-04-09 (actual); primary completion 2019-08-12 (actual). Results posted on 2021-01-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Regular Insulin vs Rapid Insulin Delivered by V-Go
Condition
Type 2 Diabetes Mellitus
Intervention (Device)
VGo
Lead sponsor
East Coast Institute for Research (class: research network)
Collaborator
Valeritas, Inc. (class: industry)
Collaborator
Dallas Diabetes Research (class: other)

Record details

Record id
cardio:ct-nct03495908
Content hash
e0551f1377b6cbcfbd69bdf218e919e3c6ccc525db92ccc31e396f189cec2d39